At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 11 enrolled
Drug / intervention
ADX-102 1% Topical Dermal Cream (reproxalap) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)
In Brief
A Phase 3 clinical trial evaluating ADX-102 1% Topical Dermal Cream (reproxalap) and Vehicle of ADX-102 Topical Dermal Cream for Sjogren-Larsson Syndrome. Completed, enrolled 11 participants across 2 sites.
Detailed Summary
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSjogren-Larsson Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartJul 2018
Primary CompletionJan 2020
TodayJul 2026
First PostedFeb 26, 2018
Enrollment StartJul 18, 2018
Primary CompletionJan 18, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.3 years ago
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap)drug
ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
Vehicle of ADX-102 Topical Dermal Creamdrug
Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.